Synucleinopathy-associated pathogenesis in Parkinson’s disease and the potential for brain-derived neurotrophic factor
Abstract The lack of disease-modifying treatments for Parkinson’s disease (PD) is in part due to an incomplete understanding of the disease’s etiology. Alpha-synuclein (α-syn) has become a point of focus in PD due to its connection to both familial and idiopathic cases—specifically its localization...
Guardado en:
Autores principales: | Kathryn M. Miller, Natosha M. Mercado, Caryl E. Sortwell |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f5cdec01b89e4bc586532d9150c98dee |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Il-10 signaling reduces survival in mouse models of synucleinopathy
por: Samuel G. Cockey, et al.
Publicado: (2021) -
Comparative proteomic analysis highlights metabolic dysfunction in α-synucleinopathy
por: Souvarish Sarkar, et al.
Publicado: (2020) -
The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?
por: Madelyn C. Houser, et al.
Publicado: (2017) -
Corrigendum: Brain-derived neurotrophic factor and its related enzymes and receptors play important roles after hypoxic-ischemic brain damage
Publicado: (2022) -
Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder
por: Ariadna Laguna, et al.
Publicado: (2021)